The advantage of the transition from conservative therapy not preserved in glaucoma. Clinical study and confocal.

(The advantage of choosing from preserved to preserved-free treatments for glaucoma. A clinical and confocal study) - MSD-007

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-004617-16-IT

Enrollment

Registered

2012-01-16

Start date

2011-11-21

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma

Interventions

Trade Name: SAFLUTAN*COLL30FL 15MCG/ML 0,3 Pharmaceutical Form: Eye drops INN or Proposed INN: TAFLUPROST Current Sponsor code: Tafluprost Concentration unit: µg/ml microgram(s)/millilitre Concentrati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: NEW DIAGNOSIS OF GLAUCOMA Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 25 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 15

Exclusion criteria

Exclusion criteria: CORNEAL PATHOLOGIES DIABETES AT ANY STAGES, HISTORY OF ACUTEANGLE CLOSURE GLAUCOMA.

Design outcomes

Primary

Measure	Time frame
Main Objective: EVALUATE CHANGES INDUCED BY TWO DRUGS ON OCULAR SURFACE IN PATIENTS WITH A NEW DIAGNOSIS OF GLAUCOMA;Secondary Objective: NO;Primary end point(s): COMPAIRE THE CONFOCAL NERVE FIBER LAYER DENSITY OF THE CORNEA IN THE FOUR LIMBAR REGIONS IN THE TWO ARMS STUDIES;Timepoint(s) of evaluation of this end point: 12 MESI	—

Secondary

Measure	Time frame
Secondary end point(s): NO;Timepoint(s) of evaluation of this end point: NO	—

Countries

Italy

Contacts

Public ContactU.O. di Oculistica

AZIENDA OSPEDALIERA S. PAOLO

luca.rossetti@unimi.it02-50323150

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026